Amprion Newsroom
Recent media coverage and announcements.
Press Release
PR Newsire
Amprion To Expand Diagnostic Testing For Neurodegenerative Disorders With Investment From Decathlon Capital Partners
July 8, 2026
Read MorePress Release
Business Wire
Amprion and Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative Disease
July 9, 2026
Read MorePress Release
PR Newswire
The Alzheimer's Drug Discovery Foundation and The Michael J. Fox Foundation Launch $5 Million Partnership to Target Key Co-Pathologies Driving Alzheimer's and Parkinson's
July 3, 2026
Read MorePress Release
PR Newswire
Amprion To Expand Diagnostic Testing For Neurodegenerative Disorders With Investment From Decathlon Capital Partners
July 8, 226
Read MoreNews Article
Drug Discovery News
Alpha synuclein reveals complexity behind Alzheimer’s and Parkinson’s diagnosis
April 21, 2026
Read MoreNews Article
Clinical Lab Products
Blood-Based Biomarkers Are Advancing Alzheimer’s Testing
July 16, 2025
Read MoreNews Article
Bio-IT World
uniQure’s Huntington’s Disease Trial Shows Promising Results
October 16, 2025
Read MoreNews Article
Clinical Leader
How Redefining The Diagnostic Odyssey Can Lead To Better Patient Outcomes
October 22, 2025
Read MorePodcast
Diagnosing Dx
The 20-Year Head Start: How Amprion Is Transforming Neurodiagnostics
December 1, 2025
Read MoreNews Article
The Pathologist
Inside the Race to Detect Neurodegenerative Disease Early
November 27, 2025
Read MoreNews Article
DiagnosticsWorld
Trendspotting: Precision Diagnostics, Artificial Intelligence, Data Management, Collection
January 6, 2026
Read MoreNews Article
PharmaVoice
New diagnostics define drug targets for Alzheimer’s, Parkinson’s and beyond
February 9, 2026
Read More
Get in the Know
Bring biological certainty to your diagnosis with Amprion's SAAmplify-É‘SYN test. Order your shipping kits today and help move your patient beyond a probable diagnosis.
